Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report

Non-small cell lung cancers (NSCLCs) with anaplastic lymphoma kinase (ALK)-rearrangement have favorable responses to ALK inhibitors. However, ALK fusion mutations harbored approximately 90 distinct fusion partners. Patients with different ALK fusions might respond distinctly to different-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Lingxin, Zheng, Jiayu, Pan, Qingyun, Liang, Yuxian, Yu, Pengli, Chen, Quanfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497211/
https://www.ncbi.nlm.nih.gov/pubmed/37706178
http://dx.doi.org/10.3389/fonc.2023.1264820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497211/
https://www.ncbi.nlm.nih.gov/pubmed/37706178
http://dx.doi.org/10.3389/fonc.2023.1264820

Ejemplares similares